ImmunoCARE: Rapid, Accurate COVID Testing to Reduce Hospitalization of Immunocompromised Individuals
Immunodeficiency, Immunosuppression, HIV Infections
About this trial
This is an interventional other trial for Immunodeficiency focused on measuring COVID-19, Immunocompromised, Advanced Age, Medicare, Medicaid
Eligibility Criteria
Inclusion Criteria: Living in the United States 18 years or older Can read and understand English Use of smartphone with bluetooth, a camera and a compatible operating system (Android OS 9.0 or higher, Apple iOS 13.0 or higher) Vaccinated against COVID-19 (completed at least the initial course, e.g. at least 2 doses of -Moderna or Pfizer, one dose of J&J) Willing and able to participate in study interventions including: Use of smartphone, including camera and bluetooth Upload verification of diagnosis, if needed Completing Surveys Use of Cue Health App Use of MyDataHelps Web or App Immunocompromised due to disease or therapy, including: Symptomatic HIV Graft versus host disease Immunoglobulin deficiency/Immunodeficiency Immunosuppressive therapy Leukemia Lymphoma (Hodgkin or non-Hodgkin) Metastatic Cancer Multiple Myeloma Solid organ malignancy Transplant, hematopoietic stem cell Transplant, solid organ Age 1. 65 years and older Able to share claims data as a member of one of the following insurance providers: Anthem BlueCross and BlueShield Anthem BlueCross Empire BlueCross BlueShield Empire BlueCross Wellpoint Carelon Unicare Simply Healthcare Plans National Government Services, Inc. MMM Health Sun HealthLink Amerigroup Medicare Medicaid Or another partner that can provide claims data on participant's behalf Exclusion Criteria: Unable to meet inclusion criteria
Sites / Locations
- Scripps ResearchRecruiting
Arms of the Study
Arm 1
Arm 2
Other
No Intervention
Intervention Arm
Control Arm
Participants in this group will complete the baseline study activities, as described above. Additionally, participants will be instructed to create a Cue Health account and download the Cue Health App. Using the app and the 10 Cue Health COVID-19 molecular tests that are provided (or Cue Health Flu+COVID molecular tests if available and FDA authorized), the participant will perform tests after exposure or if symptoms arise. Participants can also use the test for close contacts who are exposed to COVID-19 and/or have symptoms. If COVID-19 infection occurs, participants will have access to telemedicine to discuss further with a healthcare professional. When clinically indicated, medication for the treatment of COVID-19 (and/or Influenza in case of Cue Health Flu+COVID test availability) will be prescribed and delivered to the participants' delivery address. Participants can also seek care through other healthcare providers or not seek care, at their discretion.
Participants in the control group will complete the baseline study activities, as described above. If symptoms arise or COVID-19 infection occurs, participants will test and seek care as they normally would.